NCT03043313 2024-11-26Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerSeagen Inc.Phase 2 Completed117 enrolled 21 charts 1 FDA
NCT02563002 2024-10-03KEYNOTE-177Merck Sharp & Dohme LLCPhase 3 Completed307 enrolled 16 charts 2 FDA